Aethlon Medical, Inc. (AEMD)

Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET.

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.

SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026.

Aethlon Medical, Inc. (NASDAQ: AEMD - Get Free Report)'s share price passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $9.40 and traded as low as $2.66. Aethlon Medical shares last traded at $2.66, with a volume of 46,450 shares traded. Wall Street Analyst Weigh In

Aethlon Medical, Inc. (NASDAQ: AEMD - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $10.46 and traded as low as $3.05. Aethlon Medical shares last traded at $3.05, with a volume of 72,034 shares changing hands.

SAN DIEGO , Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying warrants is $4.03.

Results Support the Further Investigation of the Hemopurifier in Long COVID SAN DIEGO , Dec. 2, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today the 20 November 2025 publication of a pre-clinical study entitled "Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin" in the pre-print online archive bioRxiv: https://www.biorxiv.org/cgi/content/short/2025.11.21.689519v1. This paper has simultaneously been submitted for consideration to a peer-reviewed journal.

Aethlon Medical, Inc. ( AEMD ) Q2 2026 Earnings Call November 12, 2025 4:30 PM EST Company Participants James Frakes - CEO, CFO, Chief Accounting Officer, Secretary & Director Steven Larosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Investment Research, Inc. Jeremy Pearlman - Maxim Group LLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and welcome to the Aethlon Medical Second Quarter Fiscal 2026 Earnings and Corporate Update Conference Call.

Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m.

SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2025, at 4:15 p.m. ET on Wednesday, November 12, 2025.

SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinical trial in Australia. The study is a safety, feasibility, and dose-finding trial evaluating the company's Hemopurifier (HP) in patients with cancer not responding to anti-PD-1 therapy.

SAN DIEGO , Sept. 4, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 5,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 5,000,000 shares of common stock at a combined public offering price of $0.90 per share (or pre-funded warrant) and accompanying warrant.

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2026 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants James B. Frakes - CEO, CFO, Secretary & Director Steven P.

Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2025, and provided an update on recent developments.